Cholesterol-Targeting drug shows promise in fighting diabetic blindness
NCT ID NCT03403686
Summary
This study is testing whether a drug that activates a protein called LXR can help prevent or slow diabetic retinopathy, a common eye complication of diabetes. Researchers believe the drug works by improving how the body handles cholesterol and reducing harmful inflammation in the eye. The study will enroll 104 adults with diabetes or healthy controls to understand how the treatment works in people.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.